Is Precision Therapy an Option for Advanced Endometrial Carcinoma?

Researchers identified a highly recurrent, disease-specific PP2A PPP2R1A mutation as a driver of endometrial carcinoma and as a target for new drugs.

Source: CancerNetwork - September 5, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news